Literature DB >> 18670248

Remission of migraine attacks in a patient with depression who is taking pregabalin.

Vasilios G Masdrakis1, Panagiotis Oulis, Nikolaos A Karakatsanis, Constantin Potagas, Anastasios V Kouzoupis, Constantin R Soldatos.   

Abstract

Antiepileptic drugs (AED) are increasingly used in the treatment of migraine. Pregabalin (PGB) is an AED that has been used in the treatment of partial seizures, of various types of pain, and of certain anxiety disorders, but to the best of our knowledge, there has been no report on the use of PGB in the treatment of migraine. We report the case of a 60-year-old female inpatient with depression, long experiencing migraine, whose migraine symptoms improved markedly after receiving PGB in combination with escitalopram administered for her depression. The PGB mechanism of action in conjunction with its structural similarity with gabapentin, already successfully tested in the treatment of migraine, provide additional supportive evidence, theoretical and clinical, respectively, for PGB potential to alleviate migraine symptoms. However, only carefully randomized, controlled studies, or at the very least, open-label series of large patient samples treated in a similar fashion could establish the efficacy of PGB in migraine treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18670248     DOI: 10.1097/WNF.0b013e31814a62e1

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  2 in total

1.  Pregabalin modulation of neurotransmitter release is mediated by change in intrinsic activation/inactivation properties of ca(v)2.1 calcium channels.

Authors:  Mariano N Di Guilmi; Francisco J Urbano; Carlota Gonzalez Inchauspe; Osvaldo D Uchitel
Journal:  J Pharmacol Exp Ther       Date:  2010-12-22       Impact factor: 4.030

2.  Efficacy and tolerability of pregabalin as preventive treatment for migraine: a 3-month follow-up study.

Authors:  Raffaella Pizzolato; Veronica Villani; Luca Prosperini; Alessandro Ciuffoli; Giuliano Sette
Journal:  J Headache Pain       Date:  2011-04-09       Impact factor: 7.277

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.